PEOPLE

International Partner & Law Firm

PEOPLE

LEE, Won-Hee
Representative
List
  • Education
    Seoul National University (B.S. in Pharmacy)
    Seoul National University (M.S. in Biochemical)
    National University (Ph. D in Pharmaceutical Bioengineering)
  • Expertise
    Pharmaceutical, new natural product medicine, biotechnology, genetic engineering, stem cells, health function food, medical device, DDS, biomarker
  • Career
    Admitted to the 27th Korea Patent Bar
    Jang Patent and Law Firm(1990~1995)
    Established WON International Patent and Law Firm (1995~Present)
    Donga Pharmaceuticals Research Institute (1972~1974)
    Director, Korea Patent Attorneys Association (KPAA) (1997-1999)
    Director, Korea-U.S. Patent Attorneys Association (1997-2003)
    Director, Korean Women Entrepreneurs Association (1998-2002)
    Advisor, Development Task for biological function modulator, Ministry of Science & Technology (1998-2007)
    Committee member, Korea Patent Attorneys Association (KPAA) (1999-2001)
    Advisor, University Industrial Technology Support (1998-2010)
    Advisor, Patent Attorney Qualification Examination Committee (2001-2007)
    Director, International Association for Protection of Industrial Property in Korea (2004-2010)
    Advisor, Pharmaceutical Research Institute, Seoul National University (2004-2012)
    Director, Asian Patent Attorneys Association (APAA) (2005-2007)
    Director, LES (2006-2008)
    Vice President, Korea Patent Attorneys Association (KPAA)
    Vice President, Korean Society for Biotechnology and Bioengineering (2008-2010)
    Mediator, Offense Mediation System (2010-2012)
    Director, Woman Biological Science Forum (2010-Present)
    Advisor, Development Task for Natural Pharmaceuticals, Ministry of Health & Welfare (2011~Present)
    Vice President, Korea Business Management Research Institute (2011-Present)
    Professional Hearing Committee Member, Seoul High Court (2011-Present)
    Committee Member, Korea Trade Committee (2012~Present)
    Evaluation Committee Member, Intra-government New Drug Development Task Team (2015-Present)
    Professional Committee Member, Korea Health Industry Promotion Agency (2015-Present)
  • Representative Work
    Patent filing and patent prosecution for universities, government research institutes, SMEs for domestic and overseas
    Patent Right creation for Stillen® and Zydena® of Donga Pharmaceuticals
    Represented KOREA ATOMIC ENERGY RESEARCH INSTITUTE (KAERI) in winning Europe patent opposition case regarding zirconium alloy nuclear fuel cladding tube (2010)
    Patent Map Development Project for disease diagnosis technology – Korea Invention Promotion Association (KIPA) (2008)
    Gene therapy related super patent design support project- Korea Research Foundation (2011)
    Technology transfer business support project for stroke therapeutic agent and a composition for treating spinal cord injury -Commercialization Promotion Agency for RnD Outcomes (2013)
    RnD Consulting for 2014 2H – Commercialization Promotion Agency for R&D Outcomes (2014)
    Exosome engineering-related Patent Trend Research-KAIST (2015)
    NK cell therapeutic agent- CiM Convergence Research Center-Business Modeling Project-Korea Intellectual Property Strategy Agency (KISTA) (2016)
    Patent Linkage Support Project for medical health research regarding catheter- Korea Health Industry Development Institute (KHIDI) (2016)
    Rural Development Administration (RDA) Patent Trend Research Project for Health Functional Food in 2017 1H- Korea Intellectual Property Strategy Agency (KISTA) (2017)
  • Admission/
    Qualification
    Pharmacist
    Korea Certified Valuation Analyst
    Technology Transfer Agent
    Korea Patent Attorneys Association (KPAA)
    Korea Trademark & Design Association (KOTA)
    Asian Patent Attorneys Association (APPA)
    International Federation of Intellectual Property Attorneys (FICPI)
    Licensing Executives Society (LES)
    Korean Pharmaceutical Association (KPA)
  • Publication
    Oncology Reports, (2009) - Heat-processed neoginseng, KG-135, down-regulates G1 Cyclin-dependent kinase through the proteasome-mediated pathway in HeLa cells.
    Cancer Letter, (2010) - Potentiation of etoposide-induced apoptosis in HeLa cells by co-treatment with KG-135, a quality-controlled standardized ginsenoside formulation.
    Toxicology, (2010) - Functional inactivation of triosephosphateisomerase through phosphorylation during etoposide-induced apoptosis in HeLa cells: potential role of Cdk2.
    Studies on the Preparation and Property of Cell Proliferation Promoter Inhibitor from Soil Bacteria LPL 936
    Case Study on Patent Disputes in Pharmaceuticals Industry in WTO Era
    Trials and Decisions Case Book Regarding Genetic Engineering
    Research on EST and SNP Patents
    Genome Research and Intellectual Property Rights